Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03568058 · ClinicalTrials.gov registry record · Phase 1
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
A Phase 1 study of Advanced Cancer, sponsored by Ezra Cohen.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03568058 is a Phase 1 study of Advanced Cancer that is active but no longer recruiting, run by Ezra Cohen. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03568058, a Phase 1 study of Advanced Cancer, is active but no longer recruiting, sponsored by Ezra Cohen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG personalized vaccine
Study Locations (1)
California
- UCSD Medical Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03568058
The ClinicalTrials.gov registry entry for NCT03568058 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Ezra Cohen, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03568058 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03568058 about?
NCT03568058 is a clinical study titled "Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers". The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
What is the current status of trial NCT03568058?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-07-26. Estimated completion is 2025-12.
What conditions does trial NCT03568058 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT03568058?
The interventions under investigation include: Pembrolizumab (DRUG), personalized vaccine (DRUG).
Who is sponsoring clinical trial NCT03568058?
This trial is sponsored by Ezra Cohen, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03568058 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.